Pramipexole but not imipramine or fluoxetine reverses the "depressive-like" behaviour in a rat model of preclinical stages of Parkinson's disease.

摘要: Abstract Depression is a frequent comorbid disorder in Parkinson's disease and may antedate its motor symptoms. However, mechanisms underlying disease-associated depression are unknown current medication insufficient. The aim of the present study was to compare antidepressant-like effects imipramine, fluoxetine pramipexole model preclinical stages rats. 6-Hydroxydopamine bilaterally injected into ventrolateral region caudate-putamen This treatment induced moderate decreases levels dopamine metabolites caudate-putamen, nucleus accumbens frontal cortex reduced density tyrosine hydroxylase-immunoreactive neurons substantia nigra pars compacta ventral tegmental area. lesion increased immobility measured forced swimming test without influencing locomotor activity. Chronic (13 days) administration (1 mg/kg sc/twice day) reversed prolongation time lesioned animals but did not stimulate their locomotion. activated dopaminergic transmission brain structures which might contribute effectiveness test. In contrast, 13-day imipramine (10 mg/kg ip/day) shorten rats indicates that already induces “depressive-like” behaviour by chronic antiparkinsonian drug, pramipexole.